Israeli immunotherapy company Enlivex Therapeutics said Wednesday that 16 severe and critical COVID-19 patients who received its experimental treatment had survived a 28-day Phase II clinical trial period.
Two of the patients, who were critical cases at the start of the trial when they received the company’s Allocetra treatment, were still in intensive care and on ventilators at the end of the trial.
The other 14 patients recovered, were discharged from the hospital by the end of the trial and were reported to be healthy. The average duration of hospitalization after receiving Allocetra, for those who were discharged, was 5.3 days, the company said…
To read more visit The Times Of Israel.
CDMedia’s bank accounts were recently wiped by Deep State fraud. We need your support to put more reporters in the field! Help us here!
- Iranian Diplomat Convicted Of Terror Charges In Europe
- EU Calls On Kosovo To Open Embassy In Tel Aviv, Not Jerusalem